- Home
- XOM vs GILD Comparison
XOM vs GILD Comparison
Compare XOM & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XOM | GILD |
|---|---|---|
| Founded | 1870 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.3B | 184.4B |
| IPO Year | 2005 | 2001 |
Fundamental Metrics
Financial Performance| Metric | XOM | GILD |
|---|---|---|
| Price | $156.74 | $144.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 18 |
| Target Price | $142.30 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 15.2M | 5.1M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.62% | 2.26% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | 6.70 | ★ 6.78 |
| Revenue | ★ $332,238,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.11 | $6.10 |
| P/E Ratio | $23.48 | ★ $21.43 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $97.80 | $95.30 |
| 52 Week High | $159.61 | $157.29 |
Technical Indicators
Market Signals| Indicator | XOM | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 49.31 |
| Support Level | $112.54 | $142.93 |
| Resistance Level | $158.27 | $157.29 |
| Average True Range (ATR) | 3.74 | 3.24 |
| MACD | -0.07 | -0.99 |
| Stochastic Oscillator | 82.04 | 32.52 |
Price Performance
Historical ComparisonAbout XOM Exxon Mobil Corporation
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2024, it produced 3.0 million barrels of liquids and 8.1 billion cubic feet of natural gas per day. At the end of 2024, reserves were 19.9 billion barrels of oil equivalent, 69% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.3 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).